The [225Ac]Ac-Pr dosing experiment targeting GPA33 showed that the highest tumor-to-kidney ratios could be achieved at [225Ac]Ac-Pr mass doses between 350 and 700 pmol (Figure S5, Tables S4 and S5). Here, GPA33 is linked to neoplasm.